Nura Bio Secures $68M in Series A Funding to Pioneer Neuroprotective Therapies

Nura Bio, formerly known as Proneurotech Inc., has proudly announced the successful completion of a remarkable $68 million funding round aimed at advancing its innovative research in the realm of neuroprotective therapies. At Nura Bio, our mission is grounded in the vision that every diagnosis of a neurological disorder should be accompanied by the promise of effective treatment options, ultimately leading to a potential cure. Our groundbreaking work focuses on recent advancements in neurodegenerative pathways, enabling us to develop transformative therapies that aim to prevent neuronal loss and address neuroimmune dysregulation. This funding will significantly propel our research and development strategy, which encompasses two key approaches: the preservation of neurological function by preventing neuronal loss and the restoration of the neuron-glia axis to enhance immune responses to neurological injuries. Our lead program focuses on SARM1 inhibitors, which target a key metabolic sensor responsible for axonal degeneration—an early event observed in numerous neurological conditions. By halting this degeneration early, we are poised to make strides in treating a wide spectrum of neurological diseases, including those affecting the central, peripheral, and ocular nervous systems. This funding marks a pivotal moment in our journey toward delivering transformative solutions for patients grappling with neurological disorders, and we are excited to accelerate our multi-target pipeline to create impactful therapies that could redefine patient outcomes in the field.